The yeastSaccharomyces boulardiiis well known for its probiotic effects such as treating or preventing gastrointestinal diseases. Due to its ability to survive in stomach and intestine,S. boulardiicould be applied as a vehicle for producing and delivering bioactive substances of interest to human gut. In this study, we cloned the genelecCencoding the antilisterial peptide leucocin C from lactic acid bacteriumLeuconostoc carnosuminS. boulardii. The constructedS. boulardiistrain secreted a peptide, which had molecular weight corresponding to leucocin C in SDS-PAGE. The peptide band inhibitedListeria monocytogenesin gel overlay assay. Likewise, concentratedS. boulardiiculture supernatant inhibited the growth ofL. monocytogenes. The growth profile and acid tolerance of the leucocin C secretingS. boulardiiwere similar as those of the strain carrying the empty vector. We further demonstrated that the cells of the leucocin C producingS. boulardiiefficiently killedL. monocytogenes, also without antibiotic selection pressure. These results showed that antilisterial activity could be added to the arsenal of probiotic activities ofS. boulardii, demonstrating its potential as a carrier for therapeutics delivery.
- 416 Livsmedelsvetenskap
- 11832 Mikrobiologi och virologi